Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study

Domenico Prezioso, Riccardo Bartoletti, Massimo Cecchi, Virgilio Cicalese, Sergio Cosciani Cunico, Rocco Damiano, Antonello De Lisa, Nicola Franzolin, Bruno Frea, Giorgio Guazzoni, Ettore Mearini, Giuseppe Morgia, Giovanni Muzzonigro, Gaetano Oliva, Fausto Orestano, Arcangelo Pagliarulo, Giovanni L. Pappagallo, Paolo Parma, Massimo Perachino, Paolo PompaFrancesco Rocco, Filiberto Zattoni

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objectives: An observational study was planned by the QwABIOS group, to survey the hormonal treatment administered to prostate cancer patients in Italy within a time win dow of 12 months. We report here a prospective quality of life (QOL) evaluation over time and by hormonal treatment modalities. Methods: Patients with diagnosis of prostate cancer and treated with hormonal therapy were eligible for thh study. The EORTC QLQ-C30 v.3 questionnaire was administered at enrol ment, after 6 months and after 12 months from enrolment. Results: 587 patients were enrolled by 33 urological centers. When 1518 vuits were considered together independently of time, antiandrogen monotherapy was associated with a significantly bet ter QOL than LHRH-analogue containing treatment modalities in almost all functional scales; cyproterone acetate demonstrated a better physical function and general health status than bica lutamide. When QOL was analyzed in a prospective 12-month window, a worsening of physical function and general health status was observed; notwithstanding, antiandrogens remained signif icantly associated to a better QOL than LHRH-analogue therapies also o\er time: a favourable physical function and general health status appeared again to be related to cyproterone acetate than bicalutamide. Conclusions: Androgen deprivation therapy is associated with decline in QOL, particularly in the domains of physical function, energy, and general health status. This survey demonstrated that antiandrogens had a better QOL profile than LHRH-analogue containing therapies; furthermore, a more favourable tolerability for cyproterone acetate as compared to bicalutamide is suggested.

Original languageEnglish
Pages (from-to)99-103
Number of pages5
JournalArchivio Italiano di Urologia e Andrologia
Volume79
Issue number3
Publication statusPublished - Sep 2007

Fingerprint

Italy
Quality of Life
Cyproterone Acetate
Androgen Antagonists
Health Status
Gonadotropin-Releasing Hormone
Therapeutics
Prostatic Neoplasms
Surveys and Questionnaires
Androgens
Observational Studies

Keywords

  • Antiandrogens
  • Hormonal treatment
  • LHRH-agonists
  • Prostate cancer
  • Quality of life

ASJC Scopus subject areas

  • Nephrology
  • Urology

Cite this

Prezioso, D., Bartoletti, R., Cecchi, M., Cicalese, V., Cunico, S. C., Damiano, R., ... Zattoni, F. (2007). Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study. Archivio Italiano di Urologia e Andrologia, 79(3), 99-103.

Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study. / Prezioso, Domenico; Bartoletti, Riccardo; Cecchi, Massimo; Cicalese, Virgilio; Cunico, Sergio Cosciani; Damiano, Rocco; De Lisa, Antonello; Franzolin, Nicola; Frea, Bruno; Guazzoni, Giorgio; Mearini, Ettore; Morgia, Giuseppe; Muzzonigro, Giovanni; Oliva, Gaetano; Orestano, Fausto; Pagliarulo, Arcangelo; Pappagallo, Giovanni L.; Parma, Paolo; Perachino, Massimo; Pompa, Paolo; Rocco, Francesco; Zattoni, Filiberto.

In: Archivio Italiano di Urologia e Andrologia, Vol. 79, No. 3, 09.2007, p. 99-103.

Research output: Contribution to journalArticle

Prezioso, D, Bartoletti, R, Cecchi, M, Cicalese, V, Cunico, SC, Damiano, R, De Lisa, A, Franzolin, N, Frea, B, Guazzoni, G, Mearini, E, Morgia, G, Muzzonigro, G, Oliva, G, Orestano, F, Pagliarulo, A, Pappagallo, GL, Parma, P, Perachino, M, Pompa, P, Rocco, F & Zattoni, F 2007, 'Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study', Archivio Italiano di Urologia e Andrologia, vol. 79, no. 3, pp. 99-103.
Prezioso, Domenico ; Bartoletti, Riccardo ; Cecchi, Massimo ; Cicalese, Virgilio ; Cunico, Sergio Cosciani ; Damiano, Rocco ; De Lisa, Antonello ; Franzolin, Nicola ; Frea, Bruno ; Guazzoni, Giorgio ; Mearini, Ettore ; Morgia, Giuseppe ; Muzzonigro, Giovanni ; Oliva, Gaetano ; Orestano, Fausto ; Pagliarulo, Arcangelo ; Pappagallo, Giovanni L. ; Parma, Paolo ; Perachino, Massimo ; Pompa, Paolo ; Rocco, Francesco ; Zattoni, Filiberto. / Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study. In: Archivio Italiano di Urologia e Andrologia. 2007 ; Vol. 79, No. 3. pp. 99-103.
@article{8d56304226f34f809c60229187ee6bea,
title = "Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study",
abstract = "Objectives: An observational study was planned by the QwABIOS group, to survey the hormonal treatment administered to prostate cancer patients in Italy within a time win dow of 12 months. We report here a prospective quality of life (QOL) evaluation over time and by hormonal treatment modalities. Methods: Patients with diagnosis of prostate cancer and treated with hormonal therapy were eligible for thh study. The EORTC QLQ-C30 v.3 questionnaire was administered at enrol ment, after 6 months and after 12 months from enrolment. Results: 587 patients were enrolled by 33 urological centers. When 1518 vuits were considered together independently of time, antiandrogen monotherapy was associated with a significantly bet ter QOL than LHRH-analogue containing treatment modalities in almost all functional scales; cyproterone acetate demonstrated a better physical function and general health status than bica lutamide. When QOL was analyzed in a prospective 12-month window, a worsening of physical function and general health status was observed; notwithstanding, antiandrogens remained signif icantly associated to a better QOL than LHRH-analogue therapies also o\er time: a favourable physical function and general health status appeared again to be related to cyproterone acetate than bicalutamide. Conclusions: Androgen deprivation therapy is associated with decline in QOL, particularly in the domains of physical function, energy, and general health status. This survey demonstrated that antiandrogens had a better QOL profile than LHRH-analogue containing therapies; furthermore, a more favourable tolerability for cyproterone acetate as compared to bicalutamide is suggested.",
keywords = "Antiandrogens, Hormonal treatment, LHRH-agonists, Prostate cancer, Quality of life",
author = "Domenico Prezioso and Riccardo Bartoletti and Massimo Cecchi and Virgilio Cicalese and Cunico, {Sergio Cosciani} and Rocco Damiano and {De Lisa}, Antonello and Nicola Franzolin and Bruno Frea and Giorgio Guazzoni and Ettore Mearini and Giuseppe Morgia and Giovanni Muzzonigro and Gaetano Oliva and Fausto Orestano and Arcangelo Pagliarulo and Pappagallo, {Giovanni L.} and Paolo Parma and Massimo Perachino and Paolo Pompa and Francesco Rocco and Filiberto Zattoni",
year = "2007",
month = "9",
language = "English",
volume = "79",
pages = "99--103",
journal = "Archivio Italiano di Urologia Nefrologia Andrologia",
issn = "1120-8538",
publisher = "Edizioni Scripta Manent s.n.c.",
number = "3",

}

TY - JOUR

T1 - Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study

AU - Prezioso, Domenico

AU - Bartoletti, Riccardo

AU - Cecchi, Massimo

AU - Cicalese, Virgilio

AU - Cunico, Sergio Cosciani

AU - Damiano, Rocco

AU - De Lisa, Antonello

AU - Franzolin, Nicola

AU - Frea, Bruno

AU - Guazzoni, Giorgio

AU - Mearini, Ettore

AU - Morgia, Giuseppe

AU - Muzzonigro, Giovanni

AU - Oliva, Gaetano

AU - Orestano, Fausto

AU - Pagliarulo, Arcangelo

AU - Pappagallo, Giovanni L.

AU - Parma, Paolo

AU - Perachino, Massimo

AU - Pompa, Paolo

AU - Rocco, Francesco

AU - Zattoni, Filiberto

PY - 2007/9

Y1 - 2007/9

N2 - Objectives: An observational study was planned by the QwABIOS group, to survey the hormonal treatment administered to prostate cancer patients in Italy within a time win dow of 12 months. We report here a prospective quality of life (QOL) evaluation over time and by hormonal treatment modalities. Methods: Patients with diagnosis of prostate cancer and treated with hormonal therapy were eligible for thh study. The EORTC QLQ-C30 v.3 questionnaire was administered at enrol ment, after 6 months and after 12 months from enrolment. Results: 587 patients were enrolled by 33 urological centers. When 1518 vuits were considered together independently of time, antiandrogen monotherapy was associated with a significantly bet ter QOL than LHRH-analogue containing treatment modalities in almost all functional scales; cyproterone acetate demonstrated a better physical function and general health status than bica lutamide. When QOL was analyzed in a prospective 12-month window, a worsening of physical function and general health status was observed; notwithstanding, antiandrogens remained signif icantly associated to a better QOL than LHRH-analogue therapies also o\er time: a favourable physical function and general health status appeared again to be related to cyproterone acetate than bicalutamide. Conclusions: Androgen deprivation therapy is associated with decline in QOL, particularly in the domains of physical function, energy, and general health status. This survey demonstrated that antiandrogens had a better QOL profile than LHRH-analogue containing therapies; furthermore, a more favourable tolerability for cyproterone acetate as compared to bicalutamide is suggested.

AB - Objectives: An observational study was planned by the QwABIOS group, to survey the hormonal treatment administered to prostate cancer patients in Italy within a time win dow of 12 months. We report here a prospective quality of life (QOL) evaluation over time and by hormonal treatment modalities. Methods: Patients with diagnosis of prostate cancer and treated with hormonal therapy were eligible for thh study. The EORTC QLQ-C30 v.3 questionnaire was administered at enrol ment, after 6 months and after 12 months from enrolment. Results: 587 patients were enrolled by 33 urological centers. When 1518 vuits were considered together independently of time, antiandrogen monotherapy was associated with a significantly bet ter QOL than LHRH-analogue containing treatment modalities in almost all functional scales; cyproterone acetate demonstrated a better physical function and general health status than bica lutamide. When QOL was analyzed in a prospective 12-month window, a worsening of physical function and general health status was observed; notwithstanding, antiandrogens remained signif icantly associated to a better QOL than LHRH-analogue therapies also o\er time: a favourable physical function and general health status appeared again to be related to cyproterone acetate than bicalutamide. Conclusions: Androgen deprivation therapy is associated with decline in QOL, particularly in the domains of physical function, energy, and general health status. This survey demonstrated that antiandrogens had a better QOL profile than LHRH-analogue containing therapies; furthermore, a more favourable tolerability for cyproterone acetate as compared to bicalutamide is suggested.

KW - Antiandrogens

KW - Hormonal treatment

KW - LHRH-agonists

KW - Prostate cancer

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=35949003545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35949003545&partnerID=8YFLogxK

M3 - Article

C2 - 18041358

AN - SCOPUS:35949003545

VL - 79

SP - 99

EP - 103

JO - Archivio Italiano di Urologia Nefrologia Andrologia

JF - Archivio Italiano di Urologia Nefrologia Andrologia

SN - 1120-8538

IS - 3

ER -